National Allied Procurement Office Allows VBP Winners to Adjust MAH and Manufacturing Details
The National Allied Procurement Office has issued a notification clarifying rules for China’s Volume-Based Procurement...
Ipsen Posts 8.7% Revenue Growth in 2024, Driven by Rare Diseases and Oncology
French biopharma firm Ipsen (EPA: IPN, OTCMKTS: IPSEY) reported an 8.7% year-on-year (YOY) increase in...
Meyer FSMP Hong Kong Secures NMPA Approval for First FSMP in Greater China
Hong Kong-based Meyer FSMP Hong Kong Limited, an oncology-focused foods for special medical purpose (FSMP)...
Pfizer Halts Global Development of Hemophilia B Gene Therapy Beqvez Amid Limited Demand
Pfizer Inc. (NYSE: PFE) has terminated the development and commercialization of Beqvez (fidanacogene elaparvovec), its...
Jointown Pharmaceutical Partners with Shandong DYNE to Boost Pediatric Drug Distribution
Jointown Pharmaceutical Group Co., Ltd (SHA: 600998), China’s largest private pharmaceutical distributor, has partnered with...
CSPC Pharmaceutical Initiates Phase III Trial for Ammuxetine in Depression Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the start of a Phase III clinical...
Subtle Medical Integrates DeepSeek with FDA-Approved SupMR AI Platform
Shanghai-based Subtle Medical Inc., an AI-powered medical imaging firm operating in the U.S. and China,...
AWS Collaborates with MSK to Accelerate Oncology Research via AI and Cloud Tech
Amazon Web Services (AWS) announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK),...
Cholesgen Raises Over RMB100M in Series A to Advance Metabolic Disease Pipelines
China-based glycolipid metabolism specialist Cholesgen (Shanghai) Co. Ltd. has reportedly raised over RMB100 million ($13.8...
Innorna’s IN013 Receives FDA Rare Pediatric Designation for Wilson’s Disease Treatment
Shenzhen-based Innorna Co., Ltd, a platform company leveraging mRNA and lipid nanoparticle (LNP) delivery technologies,...
Amoytop Biotech to Acquire Skyline Therapeutics’ Gene Therapy Assets for $15M Plus Milestones
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced plans to acquire partial assets of...
Novo Nordisk’s Emerging Business Division VP Eve Jiang Departs for External Opportunities
Jiang Yiwei (Eve Jiang), corporate vice president (CVP) of Novo Nordisk’s (NYSE: NVO) Emerging Business...
Joyo Pharma’s JYP0015 Receives CDE Approval for RAS Mutation Cancer Trials
China’s Center for Drug Evaluation (CDE) has tacitly approved Joyo Pharma’s Category 1 drug JYP0015,...
Zhejiang Huahai Pharma’s HB0056 Receives NMPA Approval for Asthma Trials
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its bispecific antibody HB0056 has...
Zhejiang Dian Diagnostics Partners with Best Covered to Tackle Alzheimer’s Disease
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a China-based medical diagnostics firm, has formed a...
Grand Pharmaceutical to Boost Stake in Nanjing Kainite Medical Technology via Exercise of Partial Subscription Rights
Grand Pharmaceutical Group Limited (HKG: 0512) announced on February 21, 2025, that it plans to...
Coherent Biopharma’s CBP-1019 Granted FDA Fast Track Status for Endometrial Cancer
Coherent Biopharma Ltd, a Suzhou-based specialist in bispecific-ligand drug conjugates (Bi-XDC), announced that the U.S....
Sanofi and Teva’s Duvakitug Hits Key Milestones in UC and CD Study at ECCO Congress
Sanofi (EPA: SAN, NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) presented Phase IIb...
Triastek’s 3D-Printed Drug D23 Shows Promise in Treating IgA Nephropathy
China-based Triastek Inc., a pioneer in pharmaceutical 3D printing, announced positive outcomes from a clinical...
J&J’s Tremfya Meets All Endpoints in Phase III UC Study, Eyes FDA Approval for SC Induction
U.S. pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) presented positive results from the Phase...